Feed/Companies/Atsena Therapeutics

Atsena Therapeutics

As of 14 Oct 2026, Atsena Therapeutics has raised $150M across 1 verified round on record; latest: $150 million Series C led by Bain Capital, announced 2 Apr 2025.

BUILT ON

Visit site

Atsena Therapeutics develops gene therapies for inherited retinal diseases, targeting conditions like X-linked retinoschisis and Leber congenital amaurosis.

atsenatx.comLinkedInBiotech

LATEST ROUND

Series C

$150M · 2025-04-02

RAISED ON RECORD · USD

$150M

across 1 verified round

INVESTORS

1 lead

SOURCES

from 1 publisher

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series C

$150M · 2025-04-02

[ HISTORY ]

led by Bain Capital

Round	Amount	Announced	Lead	Buzz
Series C [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$150M	2025-04-02	Bain Capital	No recent discussion
1 source [ VERIFIED ] read against 1 source The source states that Atsena is North Carolina-based but does not specify a headquarters city. Published by hand (fiercebiotech.com): "Atsena Therapeutics has raised $150 million in an oversubscribed series C financing.": biggest-rounds completeness (K): hand-checked, the cited page states $150 million

Atsena Therapeutics

Company

Rounds

Sources

Profile

Investors

Atsena Therapeutics

Rounds

Profile

Sources

Series C$150M2025-04-021 source

Investors

Series C$150M2025-04-029 investors